<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174537</url>
  </required_header>
  <id_info>
    <org_study_id>NDV-HUJ-HMO-CTIL</org_study_id>
    <nct_id>NCT01174537</nct_id>
  </id_info>
  <brief_title>New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma</brief_title>
  <official_title>Clinical Application of Intravenous New Castle Disease Virus - HUJ Oncolytic Virus in the Treatment of Advanced Glioblastoma Multiforme, Soft and Bone Sarcomas and Neuroblastoma Patients, Resistant to Conventional Anti- Cancer Modalities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with specific metastatic cancers who failed prior therapeutic regimes will be
      treated with NDV for at least a year or until disease progression. The study will measure
      progression-free disease and posits that it will be extended.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Present therapeutic regimes have not much improved the survival of patients with metastatic
      cancer. Therapeutic cancer vaccines are a form of immunotherapy designed to educate the
      immune system to recognise tumor cells as foreign rather than self. New Castle Virus (NDV)
      has a long history as a broad system oncolytic that can destroy tumor cells and stimulate the
      immune system. Up to 30 patients suffering from recurrent, refractory Glioblastoma
      Multiforme, soft an bone sarcomas and disseminated neuroblastoma will be enrolled in this
      trial and receive daily doses of NDV at least 5 days a week for a minimum of a year or until
      disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at least 1 year</time_frame>
    <description>Measure progression-free survival of patients receiving New Castle Virus</description>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Sarcoma</condition>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>New Castle Disease Virus</intervention_name>
    <description>Patients will receive IV 1*10^10 EID50 (50 percent Embryo Infectious Dose. One EID50 unit is the amount of virus that will infect 50 percent of inoculated eggs) on a daily basis for a minimum of 5 days a week until disease progression for a minimum duration of 1 year.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of progressive disease in the above categories evaluated by standard tumor
             staging.

          -  Histologically confirmed diagnosis.

          -  Failure of conventional anti- cancer modalities.despite optimal application of all
             relevant available anti- cancer modalities.

          -  Age between 3 and 75 years old.

          -  Liver function tests less than twice the normal, renal function no more than 20%
             reduction and white cell and platelets count no more than 30% reduction.

          -  Karnofsky performance status of 50% or greater

          -  A written informed consent understood and signed by the patient and by a spouse,
             parent or guardian. In patients with GBM two signs will be required due to possible
             alterations of psych and understanding.

        Exclusion Criteria:

          -  Not fulfilling any of the above criteria

          -  Moribund patients or patients with life- expectancy &lt; 3 months

          -  Karnofksy performance status &lt; 50%

          -  Pregnant or lactating women

          -  Active local or systemic infections requiring treatment

          -  Patients receiving other investigational agents

          -  History of allergy to egg ova-albumin.

          -  Co-morbidity or life- threatening clinical condition other than the basic cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reuven Or, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Gerl R, Vaux DL. Apoptosis in the development and treatment of cancer. Carcinogenesis. 2005 Feb;26(2):263-70. Epub 2004 Sep 16. Review.</citation>
    <PMID>15375012</PMID>
  </reference>
  <reference>
    <citation>Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008 Jan;8(1):59-73. Review.</citation>
    <PMID>18097448</PMID>
  </reference>
  <reference>
    <citation>Ravindra PV, Tiwari AK, Sharma B, Chauhan RS. Newcastle disease virus as an oncolytic agent. Indian J Med Res. 2009 Nov;130(5):507-13. Review.</citation>
    <PMID>20090097</PMID>
  </reference>
  <reference>
    <citation>Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martínez-Sobrido L, Woo SL, García-Sastre A. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 2007 Sep 1;67(17):8285-92.</citation>
    <PMID>17804743</PMID>
  </reference>
  <reference>
    <citation>Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E, Siegal T. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2006 Jan;13(1):221-8. Epub 2005 Oct 28.</citation>
    <PMID>16257582</PMID>
  </reference>
  <reference>
    <citation>Nelson NJ. Scientific interest in Newcastle disease virus is reviving. J Natl Cancer Inst. 1999 Oct 20;91(20):1708-10.</citation>
    <PMID>10528013</PMID>
  </reference>
  <reference>
    <citation>Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. Int J Oncol. 2001 May;18(5):945-52.</citation>
    <PMID>11295039</PMID>
  </reference>
  <reference>
    <citation>Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000 Mar;21(3):485-95. Review.</citation>
    <PMID>10688869</PMID>
  </reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2010</study_first_submitted>
  <study_first_submitted_qc>August 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2010</study_first_posted>
  <last_update_submitted>June 10, 2015</last_update_submitted>
  <last_update_submitted_qc>June 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2015</last_update_posted>
  <responsible_party>
    <name_title>ReuvenOr</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <keyword>NDV</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Refractory</keyword>
  <keyword>Cancer</keyword>
  <keyword>Progression-free</keyword>
  <keyword>survival</keyword>
  <keyword>recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

